Cargando…

Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer

For advanced metastatic non-small-lung cancer, the landscape of actionable driver alterations is rapidly growing, with nine targetable oncogenes and seven approvals within the last 5 years. This accelerated drug development has expanded the reach of targeted therapies, and it may soon be that a majo...

Descripción completa

Detalles Bibliográficos
Autores principales: Vokes, Natalie I., Pan, Kelsey, Le, Xiuning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026098/
https://www.ncbi.nlm.nih.gov/pubmed/36950275
http://dx.doi.org/10.1177/17588359231161409
_version_ 1784909471391154176
author Vokes, Natalie I.
Pan, Kelsey
Le, Xiuning
author_facet Vokes, Natalie I.
Pan, Kelsey
Le, Xiuning
author_sort Vokes, Natalie I.
collection PubMed
description For advanced metastatic non-small-lung cancer, the landscape of actionable driver alterations is rapidly growing, with nine targetable oncogenes and seven approvals within the last 5 years. This accelerated drug development has expanded the reach of targeted therapies, and it may soon be that a majority of patients with lung adenocarcinoma will be eligible for a targeted therapy during their treatment course. With these emerging therapeutic options, it is important to understand the existing data on immune checkpoint inhibitors (ICIs), along with their efficacy and safety for each oncogene-driven lung cancer, to best guide the selection and sequencing of various therapeutic options. This article reviews the clinical data on ICIs for each of the driver oncogene defined lung cancer subtypes, including efficacy, both for ICI as monotherapy or in combination with chemotherapy or radiation; toxicities from ICI/targeted therapy in combination or in sequence; and potential strategies to enhance ICI efficacy in oncogene-driven non-small-cell lung cancers.
format Online
Article
Text
id pubmed-10026098
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-100260982023-03-21 Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer Vokes, Natalie I. Pan, Kelsey Le, Xiuning Ther Adv Med Oncol Controversies in Immunotherapy for Patients with Lung Cancer: Pragmatic Solutions For advanced metastatic non-small-lung cancer, the landscape of actionable driver alterations is rapidly growing, with nine targetable oncogenes and seven approvals within the last 5 years. This accelerated drug development has expanded the reach of targeted therapies, and it may soon be that a majority of patients with lung adenocarcinoma will be eligible for a targeted therapy during their treatment course. With these emerging therapeutic options, it is important to understand the existing data on immune checkpoint inhibitors (ICIs), along with their efficacy and safety for each oncogene-driven lung cancer, to best guide the selection and sequencing of various therapeutic options. This article reviews the clinical data on ICIs for each of the driver oncogene defined lung cancer subtypes, including efficacy, both for ICI as monotherapy or in combination with chemotherapy or radiation; toxicities from ICI/targeted therapy in combination or in sequence; and potential strategies to enhance ICI efficacy in oncogene-driven non-small-cell lung cancers. SAGE Publications 2023-03-18 /pmc/articles/PMC10026098/ /pubmed/36950275 http://dx.doi.org/10.1177/17588359231161409 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Controversies in Immunotherapy for Patients with Lung Cancer: Pragmatic Solutions
Vokes, Natalie I.
Pan, Kelsey
Le, Xiuning
Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
title Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
title_full Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
title_fullStr Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
title_full_unstemmed Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
title_short Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
title_sort efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
topic Controversies in Immunotherapy for Patients with Lung Cancer: Pragmatic Solutions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026098/
https://www.ncbi.nlm.nih.gov/pubmed/36950275
http://dx.doi.org/10.1177/17588359231161409
work_keys_str_mv AT vokesnataliei efficacyofimmunotherapyinoncogenedrivennonsmallcelllungcancer
AT pankelsey efficacyofimmunotherapyinoncogenedrivennonsmallcelllungcancer
AT lexiuning efficacyofimmunotherapyinoncogenedrivennonsmallcelllungcancer